Claims for Patent: 8,795,959

Summary for Patent: 8,795,959

Title:	Isolated glucokinase genomic polynucleotide fragments from chromosome 7
Abstract:	Provided are isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Inventor(s):	Ryan; James (Augusta, GA)
Assignee:	Ryogen LLC (Suffern, NY)
Application Number:	13/680,178
Patent Claims:	1. A method of identifying a nucleotide sequence variant of a 5'-noncoding region, 3'-noncoding region or intron region of SEQ ID NO:6, wherein said variant encodes a protein that has human glucokinase activity, wherein SEQ ID NO:6 consists of a 5'-noncoding region shown in sequence segment 1-20484 of SEQ ID NO:6, a 3'-non coding region shown in sequence segment 33461-45,980 of SEQ ID NO:6, exon regions shown in sequence segments 20485-20523, 25133-25297, 26173-26328, 27524-27643, 28535-28630, 29740-28838, 30765-30950, 31982-32134, 32867-33097, 3331433460 of SEQ ID NO:6, and intron regions shown in sequence segments 20524-25132, 25298-26172, 26329-27523, 27644-28534, 28631-28739, 28839-30764, 30951-31981, 32135-32866, 33098-33313 of SEQ ID NO:6; or its complementary sequence comprising (a) isolating genomic polynucleotide from a sample and (b) determining the presence or absence of a nucleotide sequence variation in said genomic polynucleotide by comparing the nucleotide sequence of SEQ ID NO:6 with the nucleotide sequence of the isolated genomic polynucleotide and establishing if and where a difference occurs between the two nucleic acid sequences thereby identifying a nucleotide sequence variant of SEQ ID NO:6 or its complement. 2. A method for detecting the presence of: (a) a nucleic acid molecule 45,980 nucleotides in length which is at least 99% identical to SEQ ID NO:6 which encodes a polypeptide that has human glucokinase activity, wherein SEQ ID NO:6 consists of a 5'-noncoding region shown in sequence segment 1-20484 of SEQ ID NO:6, a 3'-non coding region shown in sequence segment 33461-45,980 of SEQ ID NO:6, exon regions shown in sequence segments 20485-20523, 25133-25297, 26173-26328, 27524-27643, 28535-28630, 29740-28838, 30765-30950, 31982-32134, 32867-33097, 33314-33460 of SEQ ID NO:6, and intron regions shown in sequence segments 20524-25132, 25298-26172, 26329-27523, 27644-28534, 28631-28739, 28839-30764, 30951-31981, 32135-32866, 33098-33313 of SEQ ID NO:6; (b) a fragment of (a), comprising at least nucleotides 20485-33460 of SEQ ID NO:6 which encodes a polypeptide having human glucokinase activity and (c) a nucleic acid molecule which is a complement of the nucleic acid molecules specified in (a)-(b) in a sample, comprising contacting the sample with a polynucleotide probe comprising at least 20 contiguous nucleotides that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the polynucleotide probe binds to said nucleic acid molecule in the sample.

Details for Patent 8,795,959

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-09-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-09-21
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-09-21